CRYSVITA for FGF23-related Rickets and Osteomalacia
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
Recruiting
Observational Study
FGF23-related Hypophosphataemic Rickets and Osteomalacia
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
1 Day and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Kyowa Kirin Korea Co., Ltd. · Industry
Who this trial is looking for
This trial is looking for patients in South Korea who are using CRYSVITA. Participants will help assess the safety and effectiveness of this treatment.
Are You a Good Fit for This Trial?
You may be able to join if
I have started using CRYSVITA as approved in Korea
I agree to participate in this survey
If I am a child, my guardian has given written consent
You may not be able to join if
I cannot use CRYSVITA due to its contraindications
I want to use CRYSVITA for a different reason
I participated in pre-market clinical trials with CRYSVITA
I was taking CRYSVITA before this study started
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Patients who have been started on CRYSVITA® in accordance with the approved label in Korea
2. Those (or his/her legal guardian) who have agreed in writing to participate in the survey. Children who have obtained a written consent of his/her legal guardian about participation …
Inclusion Criteria:
1. Patients who have been started on CRYSVITA® in accordance with the approved label in Korea
2. Those (or his/her legal guardian) who have agreed in writing to participate in the survey. Children who have obtained a written consent of his/her legal guardian about participation in this survey. In case of pediatric patient, explain sufficiently what you think the patient can understand. In this case, the legal guardian may provide supplementary explanations of the survey.
Exclusion Criteria:
1. Patients for whom Burosumab is contraindicated according local label of CRYSVITA®
2. Patients who intend to use this drug for other purposes
3. Patients who participated in pre-market clinical trials with CRYSVITA® (Consecutive investigation method ONLY)
4. Patients who have been taking this drug before the starting day of this study (Consecutive investigation method ONLY)
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
